BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) - USD ($) |
Sep. 12, 2023 |
May 02, 2022 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|---|---|---|---|---|---|---|
| Acquisition | ||||||
| Contingent consideration, liability | $ 282,212,000 | $ 288,657,000 | $ 306,927,000 | $ 359,021,000 | ||
| OmicEra | ||||||
| Acquisition | ||||||
| Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 14,792,000 | |||||
| Business Combination, Consideration Transferred, Liabilities Incurred | 4,600,000 | |||||
| Cash paid related to working capital adjustment | 16,000 | |||||
| Business Combination, Consideration Transferred, Total | 19,408,000 | |||||
| Contingent consideration, liability | $ 4,600,000 | |||||
| Resolution Bioscience | ||||||
| Acquisition | ||||||
| Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 1,675,000 | |||||
| Payments to Acquire Businesses, Gross | 52,527,000 | |||||
| Business Combination, Consideration Transferred, Total | $ 54,202,000 |